Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

Gene symbol CD22 Synonyms SIGLEC-2, SIGLEC2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description CD22 molecule

GTO ID GTC0607
Trial ID ChiCTR1900025419
Disease Refractory Hematologic Cancer
Altered gene CD19|CD22
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19/CD22 CAR-T cells
Generation2nd
PhaseEarly_Phase1
Recruitment statusRecruiting
TitleCAR-T cells in the treatment of relapsed and refractory hematological malignancies
Year2019
CountryChina
Company sponsorInstitute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Vector information
Vectorlentivirus
Transgene/Inserted geneAnti-human CD22 scFv; CD8α signal peptide; 4-1BB costimulatory; CD3ζ cytoplasmic region
Viral genome modificationAnti-human CD22 scFv or anti-human CD19 scFv was linked with the CD8α signal peptide, CD8α transmembrane domain, 4-1BB costimulatory and CD3ζ cytoplasmic region and assembled into lentiviral pCDH plasmids with GFP as the tag protein.
Vector production methodThe lentiviruses were produced by transfecting HEK293T cells with CAR plasmids and packaging plasmids including PMD2.g (Invitrogen, USA), pMDLg/pRRE and pRSV-Rev (Biovector Science Lab, China). After isolation from the peripheral blood of healthy donors, T cells were cocultured with CD3/CD28 human T-activator Dynabeads (1 × 106/ml) (Gibco, USA) and recombinant human IL-2 (100-200 U/ml) (R&D, USA) in lymphocyte serum-free medium KBM581 (Corning, USA). T cells were transduced with lentiviruses for 24 h and incubated in medium changed every 2 days.
Additional featureGFP

Clinical Result

Cohort 1
Administration route None
Dosage 1E6 cells/kg
Pts 4
Lymph depletion Yes
Outcome 4/4(CR)
Adverse reactions 3/4(CRS); 1/4(Grade =3 CRS)
References PMID: 35317863

Relationship Graph

Overview of Knowledge Graph